What is the current Price Target for the LAVA Therapeutics NV stock?

The average LAVA Therapeutics NV target price is $1.83. This is 46.67% higher than the current stock price. The highest price target is 140.00%, the lowest is -20.00%. 3 Analysts have issued a price target LAVA Therapeutics NV 2026 .

How high will the LAVA Therapeutics NV stock rise?

No reliable answer can be given as to how high the LAVA Therapeutics NV stock will rise. The performance of stocks, including the LAVA Therapeutics NV stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the LAVA Therapeutics NV stock today?

The performance of LAVA Therapeutics NV stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the LAVA Therapeutics NV stock fall?

The decline in LAVA Therapeutics NV stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

LAVA Therapeutics NV Forecast, price target & analysts

$1.27

1.60% today

Nasdaq, Apr 02, 10:00 pm CET

ISIN

NL0015000AG6

Symbol

LVTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

LAVA Therapeutics NV Target price 2025 - Analyst rating & recommendation

LAVA Therapeutics NV Classifications & Recommendation:

Buy

25%

Hold

75%

LAVA Therapeutics NV Price Target

Target Price	$1.83
Price	$1.25
Potential	46.67% register free of charge
Number of Estimates	3

	3 Analysts have issued a price target LAVA Therapeutics NV 2026 . The average LAVA Therapeutics NV target price is $1.83. This is 46.67% register free of charge higher than the current stock price. The highest price target is $3.00 140.00% register free of charge , the lowest is $1.00 20.00% register free of charge .
	A rating was issued by 4 analysts: 1 Analysts recommend LAVA Therapeutics NV to buy, 3 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the LAVA Therapeutics NV stock has an average upside potential 2026 of 46.67% register free of charge . Most analysts recommend the LAVA Therapeutics NV stock at Hold.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-0.94	-1.37
	40.13%	45.74%
P/E		negative

2 Analysts have issued a LAVA Therapeutics NV forecast for earnings per share. The average LAVA Therapeutics NV EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-0.94	40.13%
2025	$-1.37 45.74% Unlock
2026	$-0.53 61.31% Unlock
2027	$-0.40 24.53% Unlock
2028	$-0.21 47.50% Unlock
2029	$-0.18 14.29% Unlock

Current	-1.21	42.11%
2025	-0.92 23.97% Unlock
2026	-2.38 158.70% Unlock
2027	-3.16 32.77% Unlock
2028	-5.95 88.29% Unlock
2029	-6.94 16.64% Unlock

LAVA Therapeutics NV...

Current LAVA Therapeutics NV Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
HC Wainwright & Co.	Locked ➜ Locked	Locked	Mar 31 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Feb 27 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Dec 20 2024
Leerink Partners	Locked ➜ Locked	Locked	Dec 12 2024
JMP Securities	Locked ➜ Locked	Locked	Dec 11 2024
JMP Securities	Locked ➜ Locked	Locked	Aug 21 2024

Analyst Rating	Date
Locked HC Wainwright & Co.: Locked ➜ Locked	Mar 31 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Feb 27 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Dec 20 2024
Locked Leerink Partners: Locked ➜ Locked	Dec 12 2024
Locked JMP Securities: Locked ➜ Locked	Dec 11 2024
Locked JMP Securities: Locked ➜ Locked	Aug 21 2024

Discover more stocks with a high price target

Coinbase Global, Inc. 81.87%

BioNTech SE - ADR 48.29%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now